Invasive aspergillosis in relapsed/refractory acute myeloid leukaemia patients: Results from SEIFEM 2016-B survey

Autor: Luisa Verga, Chiara Cattaneo, Monica Piedimonte, Rosa Fanci, Gianpaolo Nadali, Mariagrazia Garzia, Enrico Orciulo, Barbara Veggia, Angelica Spolzino, Nicola Toschi, Federica Lessi, Daniele Zama, Nicola Stefano Fracchiolla, Leonardo Potenza, Maria Chiara Tisi, Alessandro Busca, Mario Delia, Maria Ilaria Del Principe, Lucia Prezioso, Carlo Castagnola, Nunzia Decembrino, Valentina Mancini, Allegra Conti, Giulia Dragonetti, Francesco Marchesi, Sara Manetta, Anna Candoni, Michelina Dargenio, Lorella Melillo, Livio Pagano, Marco Picardi, Stelvio Ballanti, Domenico Russo
Přispěvatelé: Del Principe, Maria Ilaria, Dragonetti, Giulia, Conti, Allegra, Verga, Luisa, Ballanti, Stelvio, Fanci, Rosa, Candoni, Anna, Marchesi, Francesco, Cattaneo, Chiara, Lessi, Federica, Fracchiolla, Nicola, Spolzino, Angelica, Prezioso, Lucia, Delia, Mario, Potenza, Leonardo, Decembrino, Nunzia, Castagnola, Carlo, Nadali, Gianpaolo, Picardi, Marco, Zama, Daniele, Orciulo, Enrico, Veggia, Barbara, Garzia, Mariagrazia, Dargenio, Michelina, Melillo, Lorella, Manetta, Sara, Russo, Domenico, Mancini, Valentina, Piedimonte, Monica, Tisi, Maria Chiara, Toschi, Nicola, Busca, Alessandro, Pagano, Livio
Jazyk: angličtina
Rok vydání: 2022
Předmět:
Popis: Background: In patients with relapsed/refractory acute myeloid leukaemia (R/R AML) who received salvage chemotherapy, limited and not updated studies explored the incidence of invasive aspergillosis (IA) and the role of antifungal prophylaxis (AP). The aims of this multicentre retrospective 'SEIFEM 2016-B' study were as follows: (1) to evaluate the current rate and the outcome of proven/probable IA and (2) to assess the efficacy of AP, in a large 'real life' series of patient with R/R AML submitted to salvage chemotherapy. Results: Of 2250 R/R AML patients, a total of 74 cases of IA (5.1%) were recorded as follows: 10 (0.7%) proven and 64 (4.3%) probable. Information about AP were available in 73/74 (99%) patients. Fifty-eight (79%) breakthrough infections occurred, mainly during AP with posaconazole [25 (43%)]. The patients who received AP during salvage chemotherapy showed a benefit from antifungal therapy (AT) than patients who did not received AP [43 (86%) vs 7 (14%); p 
Databáze: OpenAIRE